Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.68 |
| ▸ | PPARA | Q07869 | 2/20 | 0.65 |
| ▸ | PPARG | P37231 | 1/20 | 0.60 |
| ▸ | REN | P00797 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.55 |
| ▸ | KLK7 | P49862 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24102984 | 1.00 | CTSS (0.68) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL7330223 | 0.91 | PPARA (0.71) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL7323154 | 0.89 | PPARA (0.69) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL5249102 | 0.88 | PPARA (0.74) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL2948482 | 0.88 | PPARA (0.74) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL2948481 | 0.88 | PPARA (0.74) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL7057772 | 0.88 | CTSS (0.64) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL10045821 | 0.88 | CTSS (0.67) | CTSSPPARAPPARGRENRAB9A | |
| SCHEMBL8123190 | 0.88 | CTSS (0.57) | CTSSPPARAPPARGRENL3MBTL1 | |
| SCHEMBL20669524 | 0.87 | CTSS (0.63) | CTSSPPARAPPARGRENRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4522621-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | Prelude Therapeutics Incorporated (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2024-01-18 | — | — | US | disclosed |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-16 | — | — | US | disclosed |
| WO-2023220577-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2023-11-16 | — | — | US | disclosed |
| WO-2023220577-A1 | 6,6A,7,8,9,10-HEXAHYDRO-5H-PYRAZINO[1',2':4,5]PYRAZINO[2,3-C]PYRIDAZINE DERIVATIVES AS SMARCA4 PROTEIN DEGRADERS FOR THE TREATMENT OF CANCER | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-116745295-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11702423-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4161935-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115867554-A | BRM targeting compounds and related methods of use | 普莱鲁德疗法有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220033409-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED | 2022-02-03 | — | — | US | disclosed |
| WO-2021252666-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-0352000-A2 | Retroviral protease binding peptides | SMITHKLINE BEECHAM CORPORATION (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033409-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | CTSS 2297/4885PPARA 4067/4885PPARG 3471/4885 |
| US-11702423-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | CTSS 2297/4885PPARA 4067/4885PPARG 3471/4885 |
| US-20230365576-A1 | BRM Targeting Compounds And Associated Methods Of Use | ABCG2, BRIX1, MRPS28 | CTSS 2375/4885PPARA 3797/4885PPARG 1888/4885 |
| US-20240018158-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRDT, RBX1 | CTSS 2297/4885PPARA 4067/4885PPARG 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.